Business Wire

NY-IFF

1.2.2021 12:52:11 CET | Business Wire | Press release

Share
IFF Unveils New Brand Identity to Accelerate Strategic Transformation

IFF (NYSE: IFF) today launched a bold new brand identity designed to propel the Company’s transformation and reinforce its leadership role in the global value chain for consumer goods and commercial products. Upon the completion of its combination with DuPont’s Nutrition & Biosciences (N&B) business, IFF will begin a new era guided by an authentic customer-centric approach and commitment to execution, deep R&D and innovation capabilities, a storied legacy of artistry and a passion to be an essential partner for its customers around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005398/en/

As part of the new brand identity, IFF has launched a new tagline, purpose, brand commitments, and cultural attributes and values. The Company believes that these brand components will support the success of the four divisions that now comprise the new IFF.

IFF’s new brand identity and tagline : Where science and creativity meet , captures the company’s longstanding focus on the dynamic interplay between artistry and science to deliver differentiated, integrated solutions to customers that amaze and delight. IFF is a force for good in its communities worldwide, accelerating sustainability-driven change across its industry.

The company’s purpose , Applying science and creativity for a better world , continues to inspire everyone at IFF to push past traditional industry boundaries and commits to be a force for a better and more sustainable future.

Core to the company’s strategy for success, a central vision: Be the partner for essential solutions , reflects its vital leadership role in the global value chain for consumer goods and commercial products, and deep commitment to be guided by a customer-centric approach in everything we do.

The IFF brand continues to be underpinned by three commitments , adapted to better reflect the new organization.

  • Question Everything : We’re here to shake things up and forge a new path. We’re working at the cutting edge of artistry and science and encourage new discoveries at every opportunity.
  • Champion Creators : We believe our differences make us great. We power companies of every shape, size and style with the ingredients, solutions and passion to convert ideas into impact.
  • Do More Good : Claiming perfection doesn’t help. We’re on a journey to do better for people and planet. Every day we bring the talent, influence and responsibility to constantly challenge the status quo.

“Today we start a transformative journey together to become a center of innovation for our customers,” said Andreas Fibig, IFF Chairman and Chief Executive Officer. “Our leadership team believes passionately in the importance and benefit of being a purpose-driven enterprise. We will lead not simply by relying on an unmatched portfolio and flawless execution, but by quickly unlocking new innovations as we tap into our shared passion for pairing science and creativity to deliver for our customers. We are creating an agile, empowered and innovative business that provides exceptional service and delivers on our commitment to be an essential partner for our customers.”

Mr. Fibig continued, “Critical to our success is our ability to foster an execution culture and embed values that support our promises to our people, customers, consumers and our communities. To that end, we have updated our cultural principles to ensure we have the foundation in place to empower our people to deliver on our commitments.”

IFF’s merger with N&B prompted the Company to establish a new set of core values and cultural principles as the foundation of its growth strategy. This resulted in the following cultural principles :

  • ACT AS AN OWNER: We take ownership and work with passion and integrity. Our teams are empowered to make decisions and help the entire organization thrive.
  • BE AGILE: We constantly push for progress and respond to the needs of our customers and the world with speed, skill, and creativity.
  • COLLABORATE AND WIN TOGETHER: Our bond with our customers and colleagues powers innovation and our shared success.

IFF’s culture is further buoyed by its values:

  • Empowerment: We make informed decisions, take action and have the courage to hold ourselves accountable for the outcomes.
  • Expertise: We collaborate, applying our collective skills and diverse backgrounds to solve problems and achieve higher levels of performance.
  • Integrity: We are inclusive, treat each other with respect and work in a fair, honest and ethical way.
  • Innovation: We harness our creativity to deliver essential solutions for our partners and the communities we serve.
  • Responsibility: We protect the health and safety of our people and preserve the communities where we work.

Introducing IFF’s Business Divisions
Nourish
The Company announced its combined Taste, Food & Beverage division will now be called Nourish. To nourish is to feed with purpose , a vision that guides IFF’s partnership with all stakeholders. Nourish, IFF’s largest division, is composed of IFF’s Taste division and N&B’s Food & Beverage segment. The new identity for Nourish better aligns the division with the enhanced capabilities, vision and purpose of the combined company as Nourish boldly imagines to create the future of food and beverage experiences.

Scent
IFF’s Scent division creates and pioneers unique fragrances, scent solutions and cosmetic actives across key consumer goods industries such as fine perfumery, personal, fabric and home care. Key enablers to these pioneering scents are unique fragrance ingredients and naturals which bring breakthrough olfactive innovation and augmented perfumery benefits. Scent leads fragrance artistry, scientific discovery and therapeutic breakthroughs that change the word for better by awakening human nature.

Health & Biosciences
Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Bioscience (H&B) platform is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. H&B works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions.

Pharma Solutions
IFF’s Pharma Solutions division is a trusted leader in developing the ingredients, products and applications that support global production of pharma and dietary supplements. With recognized brands and unmatched expertise, Pharma Solutions is setting new standards in a highly regulated industry.

To view IFF’s new brand video, visit this link . For more information about IFF’s new era at the intersection of science and creativity, visit iff.com .

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and sensorial experiences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye